19:06:07 EDT Tue 21 May 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:RVVTF - REVIVE THERAPEUTICS LTD - http://www.revivethera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RVVTF - Qnot subscribed0.0185+0.00158.8224.93220.017  0.02  0.0160.0566  0.01614:49:41Apr 2315 min RT 2¢

Recent Trades - Last 10 of 22
Time ETExPriceChangeVolume
14:49:41Q0.01850.00154,538
14:33:11Q0.018560.0015610,000
14:24:05Q0.018560.001562,000
14:11:38Q0.01850.00151,000
13:11:22Q0.018650.001651,000
12:42:32Q0.019250.002252,250
12:37:22Q0.019250.0022510,000
12:25:59Q0.020.003150
12:19:56Q0.0190.00225,500
12:19:56Q0.018750.0017525,500

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-23 07:00U:RVVTFNews ReleaseRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
2024-04-18 07:00U:RVVTFNews ReleaseRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
2024-04-02 07:30U:RVVTFNews ReleaseRevive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
2024-03-27 09:09U:RVVTFNews ReleaseRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
2024-03-19 07:00U:RVVTFNews ReleaseRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
2024-03-12 07:00U:RVVTFNews ReleaseRevive Therapeutics Provides Corporate Update
2024-02-26 16:05U:RVVTFNews ReleaseRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
2024-02-01 07:30U:RVVTFNews ReleaseRevive Therapeutics Explores the Use of Bucillamine for Long COVID
2024-01-31 17:06U:RVVTFNews ReleaseRevive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
2024-01-24 17:56U:RVVTFNews ReleaseRevive Therapeutics Ltd. Announces Offering of Up to $3 Million
2024-01-16 07:00U:RVVTFNews ReleaseRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
2024-01-10 07:00U:RVVTFNews ReleaseRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
2023-12-20 12:54U:RVVTFNews ReleaseRevive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
2023-12-18 07:00U:RVVTFNews ReleaseRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
2023-11-21 07:30U:RVVTFNews ReleaseRevive Therapeutics Provides Update of Novel Bucillamine Formulation Development
2023-11-06 07:45U:RVVTFNews ReleaseRevive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
2023-10-17 07:00U:RVVTFNews ReleaseRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
2023-10-11 08:50U:RVVTFNews ReleaseRevive Therapeutics Provides Update of Novel Bucillamine Formulation Development
2023-08-22 06:30U:RVVTFNews ReleaseRevive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
2023-07-28 07:00U:RVVTFNews ReleaseRevive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents